CVRx Shareholder Urges Board To Launch Sale Process To Unlock Barostim’s Strategic Value
Delivers Letter to the CVRx Board Highlighting Significant Value Proposition of Barostim to a Large Medical Device Company with Established Infrastructure to Capitalize on the Product's Market PositionBLOOMFIELD
A big shareholder of CVRx thinks the company should consider selling itself to a larger medical device company that could better help Barostim (their heart-device product) succeed. This is a sign some investors believe the company might be worth more if it had a bigger partner's help and resources.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.